Mineralys Therapeutics (MLYS) vs Perrigo (PRGO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Perrigo (PRGO) has outperformed Mineralys Therapeutics (MLYS) over the past year, losing 33.0% versus a loss of 40.3%. Perrigo is the larger company by market cap ($2.04 billion vs $1.99 billion), about 1.0 times the size. Perrigo pays a dividend yielding 7.86%, while Mineralys Therapeutics does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MLYS | PRGO |
|---|---|---|
| Share price | $22.54 | $14.76 |
| Market cap | $1.99B | $2.04B |
| 1-day change | +0.69% | +1.79% |
| YTD return | -38.33% | +4.17% |
| 1-year return | -40.30% | -33.03% |
| 5-year return | — | -67.58% |
| Forward P/E | — | 6.15 |
| EPS (TTM) | $-4.22 | $-12.28 |
| Dividend yield | 0.00% | 7.86% |
| Annual dividend | $0.00 | $1.16 |
| Revenue (latest FY) | — | $4.25B |
| Revenue growth (YoY) | — | -2.75% |
| Net income (latest FY) | $-154.65M | $-1.43B |
| Gross margin | — | 35.14% |
| Operating margin | — | -26.39% |
| Net margin | — | -33.51% |
| 52-week high | $47.65 | $22.02 |
| 52-week low | $21.46 | $9.23 |
| Distance from 52-week high | -52.71% | -32.97% |
| Analyst consensus | none | none |
| Avg. price target upside | +115.22% | +11.79% |
| Average volume | 1.04M | 2.80M |
| Shares outstanding | 88.41M | 138.37M |
| Employees | 76 | 8,100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Perrigo offers a meaningfully higher dividend yield (7.86% vs 0.00%).
About Mineralys Therapeutics
MLYS stock →Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
About Perrigo
PRGO stock →Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 8,100 employees
MLYS vs PRGO FAQ
Which is bigger, Mineralys Therapeutics or Perrigo?
Perrigo (PRGO) is larger, with a market capitalization of $2.04B compared with $1.99B for Mineralys Therapeutics (MLYS).
Which stock has performed better over the past year, MLYS or PRGO?
PRGO returned -33.03% over the past 12 months, compared with -40.30% for MLYS (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Mineralys Therapeutics or Perrigo?
Perrigo pays a dividend yielding 7.86%, while Mineralys Therapeutics does not currently pay a regular dividend.
Are Mineralys Therapeutics and Perrigo in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.